Literature DB >> 11453385

Malignant transformation of a gangliocytoma/ganglioglioma into a glioblastoma multiforme: a molecular genetic analysis. Case report.

Y Hayashi1, M Iwato, M Hasegawa, O Tachibana, A von Deimling, J Yamashita.   

Abstract

A gangliocytoma/ganglioglioma with no atypical or malignant features was subtotally resected from the right temporal lobe of a 16-year-old woman. A second resection was performed 8 years later to treat a locally recurrent lesion with increased cellularity that was diagnosed as a World Health Organization Grade II ganglioglioma on the basis of neuropathological examination. Molecular analysis of the recurrent tumor revealed a TP53 gene mutation, but no amplification of the epidermal growth factor receptor (EGFR) gene. Radiotherapy (60 Gy) was administered after the second resection. The patient returned 1 year later with a second focal recurrence. The specimen obtained during the third resection of tumor exhibited exclusively astrocytic differentiation, cellular pleomorphism with multinucleated cells, high mitotic activity, and endothelial proliferation. Therefore, the tumor was diagnosed to be a glioblastoma multiforme (GBM). Molecular analysis of tumor DNA from the second recurrent tumor demonstrated the presence of the TP53 mutation, which previously had been observed in the first recurrent tumor, but again no evidence of EGFR amplification. Findings demonstrate that the presence of TP53 mutation in progressed gangliogliomas should be interpreted as a progression-associated mutation rather than a consequence of treatment. This is the first report to indicate that the molecular pathways of gangliocytomas/gangliogliomas progressing to become GBMs may parallel those of diffuse astrocytomas progressing to become GBMs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453385     DOI: 10.3171/jns.2001.95.1.0138

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  14 in total

1.  Aberrant TP53 protein accumulation in the neuronal component of ganglioglioma.

Authors:  Takao Fukushima; Yoichi Katayama; Takao Watanabe; Atsuo Yoshino; Chiaki Komine; Takakazu Yokoyama
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

2.  Malignant and benign ganglioglioma: a pathological and molecular study.

Authors:  Ajay Pandita; Anandh Balasubramaniam; Richard Perrin; Patrick Shannon; Abhijit Guha
Journal:  Neuro Oncol       Date:  2007-01-26       Impact factor: 12.300

3.  Survivin expression in ganglioglioma.

Authors:  Audrey Rousseau; Michèle Kujas; Anne-Marie Bergemer-Fouquet; Rémy van Effenterre; Jean-Jacques Hauw
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

4.  Discrepant MR spectroscopic and perfusion imaging results in a case of malignant transformation of cerebral glioma.

Authors:  Wen-Chau Wu; Cheng-Yu Chen; Hsiao-Wen Chung; Chun-Jung Juan; Chun-Jen Hsueh; Hong-Wei Gao
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

Review 5.  Molecular pathogenesis of childhood brain tumors.

Authors:  Torsten Pietsch; Michael D Taylor; James T Rutka
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

6.  Genetic Characterization of a Multifocal Ganglioglioma Originating Within the Spinal Cord.

Authors:  Joshua L Wang; Christopher S Hong; Jose Otero; Vinay K Puduvalli; J Bradley Elder
Journal:  World Neurosurg       Date:  2016-09-23       Impact factor: 2.104

7.  Posterior cranial fossa gangliogliomas.

Authors:  Sam Safavi-Abbasi; Federico Di Rocco; Kraisri Chantra; Guenther C Feigl; Amr El-Shawarby; Amir Samii; Madjid Samii
Journal:  Skull Base       Date:  2007-07

8.  Adrenal Ganglioneuroma: Features and Outcomes of 42 Cases in a Chinese Population.

Authors:  Jing Xie; Jun Dai; Wen-Long Zhou; Fu-Kang Sun
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

Review 9.  Cerebellar ganglioglioma.

Authors:  Badr Fedoul; Zouhayr Souirti
Journal:  Pan Afr Med J       Date:  2012-05-22

10.  Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.

Authors:  Silvia Cases-Cunillera; Karen M J van Loo; Julika Pitsch; Anne Quatraccioni; Sugirthan Sivalingam; Paolo Salomoni; Valeri Borger; Dirk Dietrich; Susanne Schoch; Albert J Becker
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.